Keryx Biopharmaceuticals (KERX) announces that results from a Phase 3 trial of its perifosine...

|About: Keryx Biopharmaceuticals,... (KERX)|By:, SA News Editor

Keryx Biopharmaceuticals (KERX) announces that results from a Phase 3 trial of its perifosine drug failed to meet primary endpoints for improving survivability of patients with refractory advanced colorectal cancer. Shares -58.6% premarket.